Who is a QPPV — and why it matters

A Qualified Person Responsible for Pharmacovigilance (QPPV) is a designated individual within a pharmaceutical company (or appointed by a Marketing Authorization Holder, MAH) who bears ultimate responsibility for the safety monitoring of medicinal products. The QPPV’s mandate spans establishing and maintaining the company’s pharmacovigilance (PV) system, supervising safety data collection and analysis, and serving as the regulatory contact for health authorities.

In regions such as the European Union (EU), a QPPV is mandatory for any company that holds marketing authorisations for human medicinal products. This requirement stems from legislation (for example, Article 23 of Regulation (EC) No 726/2004).

Having a QPPV ensures that a robust, legally compliant pharmacovigilance system is in place — protecting patients through timely detection and management of risks, and ensuring companies remain compliant with regulatory obligations.

Key global responsibilities and regulatory expectations

Globally (e.g. in EU / international settings), the QPPV is expected to:

• Establish and maintain the PV system — including creating Standard Operating Procedures (SOPs), safety databases, processes for Individual Case Safety Reports (ICSRs), aggregate reports (PSURs, PBRERs) and risk management frameworks.
• Maintain a current Pharmacovigilance System Master File (PSMF) — a comprehensive document reflecting the PV system, responsibilities, processes, resources and safety oversight structure. The QPPV ensures that this is always inspection-ready.
• Monitor safety, detect signals, manage risk — overseeing ongoing assessment of safety data, signal detection, benefit–risk evaluation, risk minimization measures and follow-up actions.
• Serve as the primary contact for regulators 24/7 — respond to requests or queries from Competent Authorities (e.g. in case of serious adverse events), provide up-to-date safety information, and coordinate with authorities for any safety-driven regulatory actions. 
• Ensure regulatory compliance and inspection readiness — ensuring all PV activities (reporting, documentation, safety surveillance) comply with Good Pharmacovigilance Practices (GVP), national and international regulations, and that the organisation is ready for audits or inspections at any time. 

In many cases, companies may outsource the QPPV function to external experts (e.g. specialized CROs / vendors), especially when they lack internal resources or expertise — ensuring compliance while optimizing operational costs. 

Pharmacovigilance and QPPV requirements in Tanzania / East Africa — what differs

In Tanzania — under the oversight of Tanzania Medicines and Medical Devices Authority (TMDA) — pharmacovigilance is regulated under the Tanzania Medicines and Medical Devices (Pharmacovigilance) Regulations, 2018. 

Key national requirements include:

• Marketing Authorization Holders (MAHs) must establish a pharmacovigilance system for their products marketed in Tanzania. 
• Adverse drug reactions (ADRs) and other safety events must be collected, managed, and reported to TMDA. 
• Safety reporting obligations: MAHs are required to submit periodic safety reports (e.g. PSURs / PBRERs), along with any individual case safety reports (ICSRs), and to have systems for risk management and post-market surveillance. 
• Appointment of a PV focal person or responsible person: health facilities, pharmaceutical outlets, importers/distributors, and MAHs may need a PV-focal contact to manage ADR reporting and act as liaison with TMDA. 
• Integration in regional pharmacovigilance frameworks: Tanzania participates in regional initiatives such as the AU‑3S Programme, which supports pharmacovigilance systems across Africa. 

Compared to EU or other global PV systems, the Tanzanian/East African environment may involve additional challenges, such as: lower reporting rates, variable infrastructure among health facilities, limited resources for continuous safety surveillance, and the need to coordinate across different countries/regional systems when products are marketed in multiple African markets.

These realities make the role of a competent, well-trained pharmacovigilance expert — whether internal or outsourced — even more critical.

How Alcare Consultancy helps clients as a QPPV / PV partner in Tanzania / East Africa

Given your background and goals, Alcare Consultancy is well positioned to support companies needing pharmacovigilance services in Tanzania or East Africa. Here is how you can help:

• Establishing compliant PV systems

You can assist companies (local manufacturers, importers, or MAHs) in setting up a fully compliant pharmacovigilance system — from SOPs, case-reporting procedures, safety databases, to standard forms for ADR reporting. This helps ensure compliance with Tanzania’s regulations under TMDA as well as aligning with global best practices.

• Acting as PV focal point or outsourced QPPV

For companies lacking their own internal resources or expertise, Alcare Consultancy can serve as the PV focal person or external QPPV — offering a dedicated contact who understands both global standards and local regulatory obligations. You can be the bridge between the client and TMDA (or other national authorities), helping with timely safety reporting, regulatory communication, and ensuring readiness for inspections or audits.

• Safety data collection, ADR reporting and management support

Alcare Consultancy can support the collection, collation, evaluation, and reporting of ADRs / safety events from across distribution networks, healthcare facilities, and end-users — ensuring that ICSRs and aggregate safety reports (periodic reports) are prepared and submitted in line with TMDA requirements.

• Regulatory compliance and documentation maintenance (e.g. PV master file)

You can help maintain a Pharmacovigilance System Master File (PSMF) or equivalent documentation required by regulatory authorities, ensuring that all processes — risk management, safety monitoring, reporting — are documented, up to date, and auditable.

• Training, capacity building and PV culture

Beyond compliance, Alcare Consultancy can provide training to client staff, distributors, healthcare facilities — building capacity for ADR reporting, safety awareness, and embedding a culture of pharmacovigilance. This is especially relevant in settings where PV is still developing.

• Support for multi-market/regional PV strategy

For companies aiming to market products beyond Tanzania — e.g. across East Africa — Alcare Consultancy can help design and implement a harmonized PV strategy by leveraging knowledge of local regulations, regional initiatives (like AU-3S), and global best practices.

Conclusion

The role of QPPV remains central to ensuring patient safety, regulatory compliance, and sustainable pharmacovigilance practices — whether under rigorous international frameworks (such as in EU) or in evolving regulatory environments as in Tanzania and East Africa.

By combining global PV principles with local regulatory insight, Alcare Consultancy can offer a valuable service to pharmaceutical companies, importers, and other stakeholders — helping them meet their obligations, manage risk, and protect public health.

Global vs Local Pharmacovigilance Compliance — What Companies Should Know

Pharmacovigilance (PV) is inherently global: many medicines are developed for broad markets, and safety surveillance must meet international expectations. But local requirements — such as those in Tanzania or the broader East Africa region — vary. For companies operating across these jurisdictions, this creates both a challenge and an opportunity.

🌐 Global PV Expectations (e.g. EU / International Standards)

• The concept of a dedicated individual responsible for PV — a Qualified Person Responsible for Pharmacovigilance (QPPV) — originates from global regulatory frameworks. Under such frameworks the QPPV oversees the entire PV system for a Marketing Authorization Holder (MAH), including establishment and maintenance of the PV system, safety reporting, risk management, and regulatory liaison. (Wikipedia)
• The QPPV should ensure that the PV system is documented, auditable and always “inspection ready.” This includes maintaining a comprehensive PV System Master File (PSMF) describing organizational structure, roles & responsibilities, SOPs, data-management procedures, and oversight of third-party contractors or partners. (MediPharm Solutions)
• Key PV activities under global standards include: collection and evaluation of adverse event (AE) / adverse drug reaction (ADR) data (from spontaneous reports, literature, clinical trials, etc.); timely reporting of serious AEs; periodic aggregate safety reporting (e.g. periodic safety update reports — PSURs or PBRERs); risk management and signal detection; communication of safety information to regulators, healthcare professionals, and patients; and continuous review of benefit–risk profile. (Medicines Authority)
• Because of globalization, many MAHs handle products in multiple markets — meaning that PV practices must comply with diverse regulatory requirements, sometimes simultaneously. A solid global-grade PV system helps ensure compliance across jurisdictions even when laws differ.

🇹🇿 East Africa / Tanzania: Regulatory Requirements & Particularities

• In Tanzania, the regulatory authority Tanzania Medicines and Medical Devices Authority (TMDA) enforces PV requirements through the The Tanzania Food, Drugs and Cosmetics (Pharmacovigilance) Regulations, 2018. These Regulations require that each MAH/manufacturer establish and operate a pharmacovigilance quality system, designate a focal person (effectively a QPPV), and maintain a PV System Master File (PSMF) and related documentation (e.g. pharmacovigilance master plan). (Jeyflex)
• The scope is broad: pharmaceutical companies, importers/distributors, healthcare institutions, public-health programs, pharmacy outlets — all bear responsibilities for safety monitoring, AE reporting, and supporting PV systems at different levels (national, regional, community). (TGHN Media)
• MAHs are legally obliged to submit Individual Case Safety Reports (ICSRs), periodic reports (PSURs or PBRERs), Risk Management Plans (RMPs), and other safety documentation. (TMDA)
• Additionally, through regional cooperation frameworks like the AU‑3S Project — in which Tanzania participates — there is increasing harmonization and strengthening of PV systems across African countries. The project supports reporting of adverse events (including from patients and healthcare workers), signal detection, causality assessment, and links local data systems to a continental safety-data hub (Afrivigilance). (TMDA)
• For East African Community (EAC) markets, the EAC Harmonized Compendium on Safety and Vigilance spells out that MAHs must appoint a QPPV residing in at least one EAC Partner State, maintain PSMF, ensure resource access for PV duties, and meet reporting obligations (local and outside the EAC). (TMDA)

✅ What This Means for Companies (Manufacturers, Importers, MAHs)

• Having a robust PV system built to global standards (e.g. with a PSMF, documented SOPs, capable QPPV, AE/ADR collection & processing, signal-detection, periodic reporting, risk management) generally ensures compliance not only with EU/ICH-style requirements but also satisfies local Tanzanian / East African legal requirements.
• Conversely, regulatory compliance in Tanzania/EAC does not guarantee readiness for global PV inspections — because global requirements can be more stringent (e.g., faster reporting timelines, broader literature surveillance, continuous oversight of third-party partners, global safety data tracking).
• Companies operating across multiple countries must strike a balance — designing PV systems flexible enough to meet global demands, yet still aligned with local regulations and reporting mechanisms (e.g., national/regional safety-data portals, local PV focal persons, tailored Risk Management Plans).

How Alcare Consultancy Supports Clients in PV Compliance and Global + Local Alignment

At Alcare Consultancy — with its base in Dar es Salaam and experience navigating both local Tanzanian regulations and broader global PV expectations — we provide tailored support to companies aiming to comply globally and locally. Some of the ways we assist:

• PV system setup and documentation — We help clients create a full-fledged PV quality system: writing or revising SOPs; establishing a Pharmacovigilance System Master File (PSMF) and master plan; designing organizational charts; defining job descriptions for PV-responsible persons; and mapping processes for AE/ADR collection, processing, and reporting.
• Regulatory compliance audits and readiness — We conduct gap analyses comparing the client's current PV practices against both global standards (e.g. GVP-informed) and local regulation (TMDA 2018, EAC requirements). Then we propose corrective actions (CAPA), implement improvements, and support inspection readiness.
• Local regulatory liaison and submissions — For companies operating in Tanzania and/or East Africa, we act as local PV focal persons: handling submission of ICSRs, PSURs/PBRERs, Risk Management Plans, liaising with regional regulators (e.g. TMDA, EAC), and ensuring timely reporting and compliance.
• Risk management & signal detection support — We assist in designing Risk Management Plans (RMPs), setting up signal-detection procedures, literature monitoring, aggregate data analysis, and early-warning mechanisms — ensuring that safety issues are identified, assessed, and addressed both locally and globally.
• Training and capacity building — We offer training to clients’ internal staff (or their partners) in PV practices, AE reporting, SOP execution, regulatory requirements. This helps foster a safety culture and ensures that PV is embedded throughout the organization — not just relegated to a single person or department.
• Cross-jurisdiction coordination — For companies marketing products across several markets (global, East Africa, Tanzania), we help harmonize PV systems so that one core system serves multiple jurisdictions. This reduces duplication while ensuring compliance with each regulator’s demands.

In short: Alcare Consultancy acts as your “bridge” — aligning global pharmacovigilance expectations with local Tanzanian / East African regulatory reality, ensuring compliance, safety, and smooth regulatory navigation.

Challenges and Considerations — and How to Prepare

• Regulatory requirements evolve: local regulations (like TMDA’s) may be updated; regional collaborations (e.g. AU-3S) may expand scope; global standards (e.g. GVP) may get reinforced. Companies should design PV systems with flexibility in mind.
• Resource limitations are common in emerging markets: lack of local pharmacovigilance expertise, limited reporting culture among healthcare providers or patients, delays in AE reporting, limited capacity for literature surveillance. This is where outsourcing to a specialized consultancy adds value.
• Harmonization doesn’t mean “one-size-fits-all”: global templates may need adaptation for local context: language, local AE patterns, regulatory timelines, data submission formats, local public-health realities.

Conclusion

Pharmacovigilance today sits at the intersection of global standards and local regulatory demands. For companies looking to market medicines across regions — especially in East Africa and Tanzania — a well-structured PV system aligned with global good practices, yet compliant with national and regional laws, is not a luxury — it’s a necessity.

For this reason, partnering with a local, experienced consultant like Alcare Consultancy can be a strategic advantage: you get expert support in PV system design, regulatory submissions, risk management, and cross-jurisdiction compliance — freeing you to focus on your core business while safeguarding patient safety and fulfilling regulatory obligations.